CORVUS PHARMACEUTICALS INC's ticker is CRVS and the CUSIP is 221015100. A total of 54 filers reported holding CORVUS PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,966,521 | -34.0% | 1,346,932 | +3.5% | 0.00% | – |
| Q2 2023 | $2,979,805 | +159.8% | 1,301,225 | +3.2% | 0.00% | – |
| Q1 2023 | $1,147,115 | +7.1% | 1,260,566 | 0.0% | 0.00% | – |
| Q4 2022 | $1,071,481 | +3.9% | 1,260,566 | +0.1% | 0.00% | – |
| Q3 2022 | $1,031,000 | -17.8% | 1,259,906 | -0.6% | 0.00% | – |
| Q2 2022 | $1,255,000 | -39.6% | 1,267,752 | 0.0% | 0.00% | – |
| Q1 2022 | $2,079,000 | -30.0% | 1,267,752 | +2.9% | 0.00% | – |
| Q4 2021 | $2,968,000 | -49.0% | 1,231,750 | +2.4% | 0.00% | – |
| Q3 2021 | $5,824,000 | +96.6% | 1,203,363 | +8.5% | 0.00% | – |
| Q2 2021 | $2,962,000 | -3.9% | 1,109,218 | +10.9% | 0.00% | – |
| Q1 2021 | $3,081,000 | +34.5% | 1,000,119 | +55.4% | 0.00% | – |
| Q4 2020 | $2,291,000 | -5.8% | 643,580 | +6.2% | 0.00% | – |
| Q3 2020 | $2,431,000 | +55.7% | 606,114 | +5.6% | 0.00% | – |
| Q2 2020 | $1,561,000 | +28.8% | 574,227 | 0.0% | 0.00% | – |
| Q1 2020 | $1,212,000 | -61.2% | 574,227 | 0.0% | 0.00% | – |
| Q4 2019 | $3,124,000 | +80.8% | 574,227 | +0.0% | 0.00% | – |
| Q3 2019 | $1,728,000 | -5.3% | 574,091 | +17.7% | 0.00% | – |
| Q2 2019 | $1,824,000 | -1.2% | 487,636 | +6.1% | 0.00% | – |
| Q1 2019 | $1,847,000 | +116.0% | 459,397 | +97.4% | 0.00% | – |
| Q4 2018 | $855,000 | -85.3% | 232,769 | -65.7% | 0.00% | – |
| Q3 2018 | $5,817,000 | -20.3% | 677,974 | +2.0% | 0.00% | – |
| Q2 2018 | $7,295,000 | +3.5% | 664,396 | +8.7% | 0.00% | – |
| Q1 2018 | $7,045,000 | +76.1% | 611,021 | +58.2% | 0.00% | – |
| Q4 2017 | $4,000,000 | -35.0% | 386,172 | +0.0% | 0.00% | – |
| Q3 2017 | $6,155,000 | +36.2% | 386,153 | +3.4% | 0.00% | – |
| Q2 2017 | $4,520,000 | -20.1% | 373,512 | +37.1% | 0.00% | – |
| Q1 2017 | $5,660,000 | +54.4% | 272,499 | +6.3% | 0.00% | – |
| Q4 2016 | $3,666,000 | +1.2% | 256,395 | +16.4% | 0.00% | – |
| Q3 2016 | $3,624,000 | +52.4% | 220,310 | +32.1% | 0.00% | – |
| Q2 2016 | $2,378,000 | – | 166,797 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ADAMS STREET PARTNERS LLC | 3,275,616 | $28,105,000 | 4.42% |
| Novo Holdings A/S | 4,420,516 | $37,928,000 | 3.01% |
| BVF INC/IL | 1,890,507 | $16,221,000 | 1.42% |
| Orbimed Advisors | 5,967,584 | $51,202,000 | 0.62% |
| COWEN INC. | 588,706 | $5,051,000 | 0.46% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,000 | $710,000 | 0.34% |
| SPHERA FUNDS MANAGEMENT LTD. | 321,430 | $2,758,000 | 0.32% |
| EcoR1 Capital, LLC | 351,401 | $3,015,000 | 0.27% |
| Rock Springs Capital Management LP | 575,000 | $4,934,000 | 0.18% |
| Hikari Power Ltd | 32,090 | $275,000 | 0.03% |